# J. Carl Barrett

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/j-carl-barrett/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,328 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 86 |
| i10-index | 272 |
| Last Known Institution | AstraZeneca (United States) |
| OpenAlex ID | https://openalex.org/A5045263771 |
| ORCID iD | https://orcid.org/0000-0003-4042-9859 |
| Works | 572 |

## Researcher papers

- [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M](https://scholariq.org/papers/acquired-egfr-c797s-mutation-mediates-resistance-to-azd9291-in-non-small-cell/)
- [Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/association-between-plasma-genotyping-and-outcomes-of-treatment-with-osimertinib/)
- [Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial](https://scholariq.org/papers/olaparib-combined-with-chemotherapy-for-recurrent-platinum-sensitive-ovarian/)
- [Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-as-first-line-treatment-of-i-egfr-i-mutation-positive-advanced-non/)
- [Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/establishing-guidelines-to-harmonize-tumor-mutational-burden-tmb-in-silico/)
- [EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291](https://scholariq.org/papers/egfr-mutation-detection-in-ctdna-from-nsclc-patient-plasma-a-cross-platform/)
- [Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA](https://scholariq.org/papers/tracking-early-lung-cancer-metastatic-dissemination-in-tracerx-using-ctdna/)
- [Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study](https://scholariq.org/papers/mechanisms-of-acquired-resistance-to-first-line-osimertinib-preliminary-data/)
- [Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/aligning-tumor-mutational-burden-tmb-quantification-across-diagnostic-platforms/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [AstraZeneca (United States)](https://scholariq.org/institutions/astrazeneca-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.